Clonal Cytogenetic Abnormalities in Philadelphia Chromosome Negative Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib

References

• Shtivelman, E., Lifshitz, B., Gale, R.P. and Canaani, E. (1985) "Fused transcript of abl and bcr genes in chronic myelogenous leukaemia", Nature, 315, 550— 554.
   Google Scholar
• Bartram, CR., de Klein, A., Hagemeijer, A., van Agthoven, T., Geurts van Kessel, A., Bootsma, D., et al. (1983) "Translocation of c-ab 1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia", Nature, 306, 277 — 280.
   PubMed Web of Science ®Google Scholar
• Nowell, P.C. and Hungerford, D.A. (1960) "A minute chromosome in human chronic ganulocytic leukemia", Science, 132, 1497. Abstract.
   Google Scholar
• Rowley, J.D. (1973) "Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quina-crine fluorescence and Giemsa staining", Nature, 243, 290–293.
   Google Scholar
• Daley, G.Q., Van Etten, R.A. and Baltimore, D. (1990) "Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome", Science, 247, 824–830.
   PubMed Web of Science ®Google Scholar
• Cervantes, F. (2003) "Durability of responses to Imatinib in newly diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML): 24-Month Update from the IRIS Study", Blood, 102, 181a. Abstract.
   Google Scholar
• Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., et al. (2002) "Hematologic and cytoge-netic responses to imatinib mesylate in chronic myelogenous leukemia", N. Engl. J. Med., 346, 645–652.
   PubMed Web of Science ®Google Scholar
• O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003) "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", N. Engl. J. Med., 348, 994–1004.
   Google Scholar
• Mitelman, F., Levan, G., Nilsson, P.G. and Brandt, L. (1976) "Non-random karyotypic evolution in chronic myeloid leukemia", Int. J. Cancer, 18, 24–30.
   PubMed Web of Science ®Google Scholar
• Lawler, S.D., O'Malley, F. and Lobb, D.S. (1976) "Chromosome banding studies in Philadelphia chromosome positive myeloid leukaemia", Scand. J. HaematoL, 17, 17–28.
   PubMedGoogle Scholar
• Johansson, B., Fioretos, T., Billstrom, R. and Mitelman, F. (1996) "Abberant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha", Leukemia, 10, 1134 — 1138.
   Google Scholar
• Nanjangud, G., Kadam, P.R., Saikia, T., Bhisey, AN., Kumar, A., Gopal, R., et al. (1994) "Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis", Leuk. Res., 18, 385–392.
   Google Scholar
• Swolin, B., Weinfeld, A., Westin, J., Waldenstrom, J. and Magnusson, B. (1985) "Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progres-sion", Cancer Genet. Cytogenet., 18, 65–79.
   Google Scholar
• Hild, F., Freund, M. and Fonatsch, C. (1991) "Chromosomal aberrations during interferon therapy for chronic myelogenous leukemia", N. Engl. J. Med., 325, 132. Letter.
   Google Scholar
• Maloisel, F., Uettwiller, F., Laplace, A., Lioure, B., Herbrecht, R., Mark, M., et al. (1999) "Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia", Cancer Genet. Cytogenet., 113, 172 — 176.
   Google Scholar
• Chase, A., Pickard, J., Szydlo, R., Coulthard, S., Goldman, J.M. and Cross, N.C. (2000) "Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia", Genes Chromosomes Cancer, 27, 278 — 284.
   PubMed Web of Science ®Google Scholar
• Bilhou-Nabera, C., Bernard, P., Marit, G., Viard, F., Gharbi, M.J., Wen, Z., et al. (1992) "Serial cytogenetic studies in allografted patients with chronic myeloid leukemia", Bone Marrow Transplant, 9, 263–268.
   Google Scholar
• Sessarego, M., Frassoni, F., Defferrari, R., Bacigalupo, A., Fugazza, G., Mareni, C., et al. (1991) "Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in ad-vanced phases of the disease after allogeneic bone marrow transplantation", Cancer Genet. Cytogenet., 57, 69— 78.
   Google Scholar
• Marktel, S., Mann, D., Foot, N., Szydlo, R., Bua, M., Karadimi-tris, A., et al. (2003) "Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression", Haematologica, 88, 260— 267.
   Web of Science ®Google Scholar
• Mohamed, AN., Pemberton, P., Zonder, J. and Schiffer, C.A. (2003) "The effect of imatinib mesylate on patients with Philadel-phia chromosome-positive chronic myeloid leukemia with second-ary chromosomal aberrations", Clin Cancer Res., 9, 1333–1337.
   PubMed Web of Science ®Google Scholar
• Bilhou-Nabera, C., Marit, G., Devianne, I., Viard, F., Salzes, S., Montastruc, M., et al. (1993) "A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia", Genes Chromosomes Cancer, 6, 255–226.
   PubMed Web of Science ®Google Scholar
• Ariyama, T., Inazawa, J., Uemura, Y., Kakazu, N., Maekawa, T., Urase, F., et al. (1995) "Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of alpha-interferon therapy for Ph positive chronic myelocytic leukemia", Cancer Genet. Cytogenet., 81, 20–23.
   Google Scholar
• Casali, M., Truglio, F., Milone, G., Di Raimondo, F., Parrinello, G., Maserati, E., et al. (1992) "Trisomy 8 in Philadelphia chromosome (Phi )-negativecells in the course of Phi -positive chronic myelocytic leukemia", Genes Chromosomes Cancer, 4, 269 — 270.
   Web of Science ®Google Scholar
• Izumi, T., Imagawa, S., Hatake, K., Miura, Y., Ariyama, T., Inazawa, J., et al. (1996) "Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Phi-positive chronic myelogenous leukemia", Int. J. HematoL, 64, 73 — 77.
   Google Scholar
• Fayad, L., Kantarjian, H., O'Brien, S., Seong, D., Albitar, M., Keating, M., et al. (1997) "Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases", Leukemia, 11, 767–771.
   PubMed Web of Science ®Google Scholar
• Shepherd, P., Brito-Babapulle, F., Duncombe, A., Parker, A., Parry, H., Winfield, D., et al. (1996) "Acute blast transformation in CML patients still showing cytogenetic response to IFN-nl and the presence of cytogenetic abnormalities in Ph negative cells", Br. J. HaematoL, 93, 72. Abstract 282.
   Google Scholar
• Alimena, G., Breccia, M., Mancini, M., Ferranti, G., De Felice, L., Gallucci, C., et al. (2004) "Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome", Leukemia, 18, 361 — 362.
   Google Scholar
• Goldberg, S.L., Madan, R.A., Rowley, S.D., Pecora, AL., Hsu, J.W. and Tantravahi, R. (2003) "Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy", Blood, 101, 781.
   PubMedGoogle Scholar
• Andersen, M.K., Pedersen-Bjergaard, J., Kjeldsen, L., Dufva, I.H. and Brondum-Nielsen, K. (2002) "Clonal Ph-negative hematopoi-esis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8", Leukemia, 16, 1390— 1393.
   Web of Science ®Google Scholar
• Besalduch, J., Gutierrez, A., Rosell, J., Bernues, M. and Sampol, A. (2002) "Abnormal cytogenetic evolution in a case of CML treated by imatinib mesylate", Blood, 100, 33 lb.
   Google Scholar
• Bumm, T., Muller, C., Al Ali, H.K., Krohn, K., Shepherd, P., Schmidt, E., et al. (2003) "Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority", Blood, 101, 1941 — 1949.
   Web of Science ®Google Scholar
• Cervetti, G., Galimberti, S., Fazzi, R., Papineschi, F., Azzara, A., Simi, P., et al. (2004) "Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib", Eur. J. Clin. Invest., 34, 243–244.
   Google Scholar
• Herens, C., Baron, F., Croisiau, C., Tassin, F. and Bours, V. (2003) "Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases", Cancer Genet. Cytogenet., 147, 78 —80.
   Google Scholar
• Feldman, E., Najfeld, V., Schuster, M., Roboz, G., Chadburn, A. and Silver, R.T. (2003) "The emergence of Ph-, trisomy-8 + cells in patients with chronic myeloid leukemia treated with imatinib mesylate", Experimental Hematology, 31, 702–707.
   PubMed Web of Science ®Google Scholar
• Gozzetti, A., Tozzuoli, D., Crupi, R., Gentili, S., Bocchia, M., Raspadori, D., et al. (2003) "Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI)", European Journal of Haematology, 71, 313 — 314.
   Google Scholar
• Gambacorti-Passerini, C., Giudici, G., le Coutre, P., Bungaro, S., Pogliani, E., Kreuzer, K.A., et al. (2001) "Non random chromo-somal abnormalities in Ph-negative bone marrow (BM) cells from CML patients achieving major cytogenetic responses (MCR) with ST171 (GleevecTM)", Blood, 98, 257b.
   Google Scholar
• Meeus, P., Demuynck, H., Martiat, P., Michaux, L., Wouters, E. and Hagemeijer, A. (2003) "Sustained, clonal karyotype abnormal-ities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib", Leukemia, 17, 465–467.
   Google Scholar
• Medina, J., Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Faderl, S., et al. (2002) "Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients (pts) with Ph positive chronic myeloid leukemia (CML) in chronic phase (CP)", Blood, 100, 368a.
   Google Scholar
• McMullin, M.F., Humphreys, M., Byrne, J., Russell, N.H., Cuthbert, R.J. and O'Dwyer, M.E. (2003) "Chromosomal abnorm-alities in Ph- cells of patients on imatinib", Blood, 102, 2700— 2701; author reply 2701.
   Google Scholar
• O'Dwyer, M.E., Gatter, K.M., Loriaux, M., Druker, B.J., Olson, S.B., Magenis, R.E., et al. (2003) "Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate", Leukemia, 17, 481–487.
   Google Scholar
• Schoch, C., Haferlach, T., Kern, W., Schnittger, S., Berger, U., Hehlmann, R., et al. (2003) "Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate", Leukemia, 17, 461 —463.
   Google Scholar
• Sun, G., Boczkowska, B., Tcheurekdjian, L., Lorenzo, M. and Owens, M. (2002) "The emergence of cytogenetically unrelated clones may not be an uncommon finding in imatinib mesylate-treated CML", Blood, 100, 326b. Abstract.
   Google Scholar
• Snyder, D.S., Slovak, M.L., Bhatia, R. and Arber, D. (2002) "Philadelphia chromosome negative clones in Philadelphia chromo-some positive CML: emerging clinical implications in eight cases", Blood, 100, 322b. Abstract.
   Google Scholar
• Symeonidis, A., Kouraklis-Symeonidis, A., Lambropoulou, V., Giannaloulas, N., Fragopanagou, E., Tinikou, M., et al. (2003) "Emergence of Abnormal Cytogenetic Abnormalities after Treat-ment of Patients with bcr/abl + Chronic Myelogenous Leukemia with Imatinib", Blood, 102, 318b. Abstract.
   Google Scholar
• Meunier, V., Giraudier, S., Van den Aker, J., Perot, C., Jouault, H., Caron-Servan, B., et al. (2001) "Treatment with STI571 (Novar-tisR) in chronic myeloid leukemia (CML): unexpected hematologi-cal findings in a series of 26 patients", Blood, 98, 263b.
   Google Scholar
• ISCN. (1995) An International System for Human Cytogenetic Nomenclature, edited by F. Mitelman. Basel: S. Karger.
   Google Scholar
• Royer-Pokora, B., Hildebrandt, B., Redmann, A., Herold, C., Kronenwett, R., Haas, R., et al. (2003) "Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment", Leukemia, 17, 807 —810.
   Web of Science ®Google Scholar
• Vickers, M. (1996) "Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data", Br. J. Haematol., 94, 1–4.
   Google Scholar
• Raskind, W.H., Ferraris, AM., Najfeld, V., Jacobson, R.J., Moohr, J.W. and Fialkow, P.J. (1993) "Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia", Leukemia, 7, 1163–1167.
   Google Scholar
• Fialkow, P.J., Martin, P.J., Najfeld, V., Penfold, G.K., Jacobson, R.J. and Hansen, J.A. (1981) "Evidence for a multistep pathogen-esis of chronic myelogenous leukemia", Blood, 58, 158 — 163.
   Google Scholar
• Spencer, A. and Granter, N. (1999) "Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation", Exp. He-matol., 27, 1397–1401.
   Google Scholar
• Bergamaschi, G., Podesta, M., Frassoni, F., Rosti, V., Carella, AM., Saglio, G., et al. (1994) "Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia auto-grafted with Ph-negative peripheral stem cells", Br. J. HaematoL, 87, 867–870.
   Web of Science ®Google Scholar
• Mauro, M.J., Loriaux, M. and Deininger, M.W. (2004) "Ph-positive and -negative myeloproliferative syndromes may co-exist", Leuke-mia.
   Google Scholar
• Ganti, AK., Potti, A. and Mehdi, S.A. (2003) "Chromosomal anomalies in two coexistent myeloproliferative disorders", Cancer Genet. Cytogenet., 145, 172— 175.
   Google Scholar
• Yuan, Z.M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y.Y., et al. (1999) "p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage", Nature, 399, 814–817.
   PubMed Web of Science ®Google Scholar
• Shafman, T., Khanna, K.K., Kedar, P., Spring, K., Kozlov, S., Yen, T., et al. (1997) "Interaction between ATM protein and c-Abl in response to DNA damage", Nature, 387, 520–523.
   Google Scholar
• Kharbanda, S., Pandey, P., Jin, S., Inoue, S., Bharti, A., Yuan, Z.M., et al. (1997) "Functional interaction between DNA-PK and c-Abl in response to DNA damage", Nature, 386, 732–735.
   Google Scholar
• Heinrich, MC., Griffith, D.J., Druker, B.J., Wait, CL., Ott, K.A. and Zigler, A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor", Blood, 96, 925–932.
   PubMed Web of Science ®Google Scholar
• Lowry, P.A., Zsebo, KM., Deacon, D.H., Eichman, C.E. and Quesenberry, P.J. (1991) "Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from SCA + Lin- murine hemato-poietic progenitors", Exp. Hematol., 19, 994–996.
   Web of Science ®Google Scholar
• Migliaccio, G., Migliaccio, AR., Valinsky, J., Langley, K., Zsebo, K., Visser, J.W., et al. (1991) "Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells", Proc. Natl. Acad. Sci. USA, 88, 7420–7424.
   PubMed Web of Science ®Google Scholar
• Lyman, S.D. and Jacobsen, S.E. (1998) "c-kit ligand and F1t3 ligand: stem/progenitor cell factors with overlapping yet distinct activities", Blood, 91, 1101 — 1134.
   Google Scholar
• Heaney, M.L. and Golde, D.W. (1999) "Myelodysplasia", N. Engl. J. Med., 340, 1649 — 1660.
   Web of Science ®Google Scholar
• Olney, Hi. and Le Beau, M.M. (2001) "The cytogenetics of myelodysplastic syndromes", Best Practitioners. Res. Clin. Haema-toL, 14, 479–495.
   PubMed Web of Science ®Google Scholar